Ticker Details
Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.
IPO Date:	February 12, 2014
Sector:	Healthcare
Industry:	Drug Manufacturers
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.98 | 8.39%
Avg Daily Range (30 D):	$0.16 | 83.13%
Avg Daily Range (90 D):	$0.15 | 60.01%

Institutional Daily Volume
Avg Daily Volume:	.17M
Avg Daily Volume (30 D):	M
Avg Daily Volume (90 D):	M

Trade Size
Avg Trade Size (Sh.):	81
Avg Trade Size (Sh.) (30 D):	545
Avg Trade Size (Sh.) (90 D):	1,172

Institutional Trades
Total Institutional Trades:	2,324
Avg Institutional Trade:	$1.52M
Avg Institutional Trade (30 D):	$1M
Avg Institutional Trade (90 D):	$1M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.5M
Avg Closing Trade (30 D):	$.76M
Avg Closing Trade (90 D):	$.76M
Avg Closing Volume:	31.5K

News

Dec 24, 2025 @ 5:30 PM HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS,... Source: Prnewswire

Oct 6, 2025 @ 11:30 PM Eagle Pharmaceuticals Announces Availability of Un... Source: Na

Aug 28, 2025 @ 11:30 PM Eagle Pharmaceuticals to Appoint Abhinav Jain to i... Source: Na

Oct 14, 2024 @ 10:13 PM Snowflake, Eagle Pharmaceuticals, Blue Ridge Banks... Source: Johnson Fistel, Llp

Oct 10, 2024 @ 5:00 PM Global Antiemetics Drugs Market to Exhibit Growth ... Source: Delveinsight

Financials
	TTM	Q2 2023	Q1 2023
Basic EPS	$.92	$.39	$.44
Diluted EPS	$.91	$.39	$.44
Revenue	$257.55M	$64.65M	$66.31M
Gross Profit	$184.28M	$47.79M	$49.01M
Net Income / Loss	$11.95M	$5.16M	$5.75M
Operating Income / Loss	$41.01M	$10.3M	$11.77M
Cost of Revenue	$73.27M	$16.86M	$17.3M
Net Cash Flow	$-21.21M	$-6.54M	$-33.42M
PE Ratio